磷酸西格列汀对2型糖尿病患者血脂的影响

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the impact of sitagliptin phosphate on blood lipid of patients with type 2 diabetic. Methods 40 patients with type 2 diabetic admitted into our hospital from July 2013 to November 2014 were selected. All patients were treated with sitagliptin phosphate（100 mg,once a day）for 24 weeks.The changes of fasting blood glucose,2 hours postprandial hyperglycemia,glycosylated hemoglobin,body weight index,blood lipid and blood uric acid in patients were observed before and after treatment. Results Compared with treatment for 12 weeks and before treatment, the level of fasting blood glucose,postprandial hyperglycemia,glycosylated hemoglobin was decreased（P＜0.05）,body weight index,total cholesterol,triglyceride,high density lipoprotein cholesterol,low density lipoprotein cholesterol and blood uric acid had no obvious change（P＞0.05）.Compared with treatment for 24 weeks and before treatment,the level of fasting blood glucose,postprandial hyperglycemia,glycosylated hemoglobin,total cholesterol,triglyceride and low density lipoprotein cholesterol was obvious decreased（P＜0.05）,but body weight index,high density lipoprotein cholesterol and blood uric acid had no obvious change（P＞0.05）. Conclusion Sitagliptin phosphate can effective control blood glucose of patients with type 2 diabetic and improve blood lipid level.

Key words： Sitagliptin phosphate Type 2 diabetes Blood glucose Blood lipid

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Ying
	ZOU Shui-lan
	KONG Xia

Cite this article:

LU Ying,ZOU Shui-lan,KONG Xia. Impact of sitagliptin phosphate on blood lipid of patients with type 2 diabetes[J]. 中国当代医药, 2016, 23(2): 121-123.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I2/121

[1]	中华医学会糖尿病学分会.中国2型糖尿病防治指南（2013年版）[J].中华糖尿病杂志，2014，6（7）：447-448.
[2]	de Valk HW.DPP-4 inhibitors and combined treatment in type 2 diabetes:re-evaluation of clinical success and safety[J].Rev Diabet Stud，2007，4（3）：126-133.
[3]	Chia CW，Egan JM.Incretin-based therapies in type 2 diabetes mellitus[J].Clin Endocrinol Metab，2008，93（10）：3703-3716.
[4]	Drucker DJ.Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes:preclinical biology and mechanisms of action[J].Diabetes Care，2007，30（6）：1335-1343.
[5]	Tian L，Gao J，Hao J，Zhang Y，et al.Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidaseⅣinhibitor[J].Endocrinology，2010，151 （7）：3049-3060.
[6]	Herman-Hermen W，Johnson J，Teng R，et al.Efficacy and safety of initial combination therapy with sitagliptin andmetformin in patients with type 2 diabetes：a 54-week study[J].Curr Med Res Opin，2009，25（3）：569-583.
[7]	Herman DW，Johnson J，TengR，et al.Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes[J].Diabetes Obes Metab，2010，12（5）：442-451.
[8]	Vilsll T，Rosenstock J，Yki-J rvinen H，et al.Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes [J].Diabetes Obes Metab，2010，12（2）：167-177.
[9]	Migoya EM，Stevens CH，Bergman AJ，et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of pharmacokinetics of sitagliptin[J].Can J Clin Pharmacol，2009，16（1）：165-170.
[10]	Raz I，Chen Y，Wu M，et al.Efficacy and safety of Sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes [J]. Curr Med Res Opin，2008，24（2）：537-550. [11] Nonaka K，Kakikawa T，Sato A，et al.Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes [J].Diabetes Res Clin Pract，2008，79（2）：291-298.
[12]	Hermansen K，Kipnes M，Luo E，et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor,sitagliptin,in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin[J].Diabetes Obes Metab，2007，9（5）：733-745.
[13]	Aschner P，Katzeff HL，Guo H，et al.Efficacy and safety of monotherapy of sitagliptin compared with metformin inpatients with type 2 diabetes[J]. Diabetes Obes Metab，2010，12（1）：1-10.
[14]	Iwamoto Y，Tajima N，Kadowaki T，et al.Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes：a randomized，double blind trial[J].Diabetes Obes Metab，2010，12（7）：613-622.
[15]	Boschman M，Engeli S，Dobberstein K，et al.Dipeptidyl peptidaseⅣinhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients[J].J Clin Endocrinol Metab，2009，94（3）：846-852.
[16]	Karasik A，Charbonnel B，Liu J，et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J]. Diabetes Care，2006，29（12）：2638-2643.